Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-c...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

pipilongstocking Jul. 4 at 8:11 PM

$AVXL https://youtu.be/p31snYad0r4?is=-A0ojCFRf_PsxPgR

0 · Reply

MoneyHungry101 Jul. 4 at 1:01 AM

$AVXL @MayoMobile what is your personal opinion after going through the full report? Are you still holding same position or made any changes? If you like to share? TIA

3 · Reply

pipilongstocking Jul. 3 at 9:48 PM

$AVXL https://x.com/tuckercarlson/status/2073089491896791320?s=46

4 · Reply

Sand_Pebble Jul. 3 at 4:52 PM

$AVXL I thought the markets would do a half day today? Nice to see the '76 ending of the shares price over the Independence Day Weekend. 2.50 would have been appropriate too but '76 is better. Happy 250th Independence Day to all. Try not to blow any fingers off.

0 · Reply

old_salt Jul. 3 at 2:09 PM

$AVXL 💪

0 · Reply

Goodhealth Jul. 3 at 11:03 AM

$AVXL https://www.nature.com/articles/s41556-026-02009-4

0 · Reply

Littlewolf71 Jul. 2 at 11:31 PM

$AVXL

0 · Reply

AntonioChigurh Jul. 2 at 11:29 PM

$AVXL from $31.50 to $2.73 Great Ride!!

0 · Reply

Series4Guy Jul. 2 at 9:24 PM

$AVXL no news today is good news

1 · Reply

Public_Accountant1 Jul. 2 at 7:53 PM

$AVXL For those wondering about the late earnings call. Expect something within the next 2 weeks or so. Delisting is a serious concern now that we are about 2 weeks away with no communication from the Company.

2 · Reply

Anavex receives expected Nasdaq delinquency notification

May 22, 2026, 8:00 AM EDT - 6 weeks ago

Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification

2026-05-11T23:30:42.000Z - 7 weeks ago

Anavex delays 10Q filing

2026-05-07T04:34:31.000Z - 2 months ago

Anavex Life Sciences names Terrie Kellmeyer interim CEO, succeeding Missling

May 6, 2026, 7:00 AM EDT - 2 months ago

Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

2026-05-04T11:06:52.000Z - 2 months ago

Anavex initiated with a Buy at Rodman & Renshaw

Apr 14, 2026, 1:30 PM EDT - 2 months ago

Anavex Life Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease

Apr 7, 2026, 7:30 AM EDT - 3 months ago

Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

2026-03-30T11:49:59.000Z - 3 months ago

Anavex gives update after blarcamesine marketing authorization withdrawal

Mar 30, 2026, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Provides Comprehensive Regulatory Update

2026-03-25T11:40:45.000Z - 3 months ago

Anavex withdraws marketing authorization application for blarcamesine in the EU

Mar 25, 2026, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease

2026-03-23T11:45:08.000Z - 3 months ago

Anavex presents new data from ANAVEX2-73-AD-004 program

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease

Mar 20, 2026, 7:30 AM EDT - 3 months ago

New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease

2026-03-17T11:40:32.000Z - 3 months ago

Anavex presents treatment effects of blarcamesine in Parkinson’s model

Mar 17, 2026, 7:30 AM EDT - 3 months ago

Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference

Mar 3, 2026, 7:30 AM EST - 4 months ago

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Mar 2, 2026, 11:50 AM EST - 4 months ago

Anavex Life Sciences Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 7:30 AM EST - 4 months ago

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

2026-02-23T12:45:54.000Z - 4 months ago

Anavex appoints Paeger to Board of Directors

Feb 23, 2026, 7:30 AM EST - 4 months ago

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

Feb 9, 2026, 8:30 AM EST - 5 months ago

Anavex Life Sciences Earnings Call Transcript: Q1 2026

Feb 9, 2026, 8:30 AM EST - 5 months ago

Anavex Life Sciences Earnings release: Q1 2026

Feb 9, 2026, 8:30 AM EST - 5 months ago

Anavex Life Sciences Quarterly report: Q1 2026

Feb 9, 2026, 7:30 AM EST - 5 months ago

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Feb 3, 2026, 7:30 AM EST - 5 months ago

Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

Jan 14, 2026, 7:30 PM EST - 6 months ago

Anavex Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-13T12:41:18.000Z - 6 months ago

Anavex joins ACCESS-AD, initiative for therapeutic approaches for Alzheimer’s

Jan 13, 2026, 7:30 AM EST - 6 months ago

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease

2026-01-08T12:35:17.000Z - 6 months ago

Anavex appoints Wolfgang Liedtke as SVP, global head of neurologyRegeneron

REGN

Jan 8, 2026, 7:30 AM EST - 6 months ago

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

2026-01-06T12:36:17.000Z - 6 months ago

Anavex receives FDA feedback on Alzheimer’s disease program

Jan 6, 2026, 7:30 AM EST - 6 months ago

Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program

2025-12-18T12:35:52.000Z - 7 months ago

Anavex submits request for EMA to re-examine its opinion on blarcamesine

Dec 18, 2025, 7:30 AM EST - 7 months ago

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

Nov 26, 2025, 7:30 AM EST - 7 months ago

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 25, 2025, 8:30 AM EST - 7 months ago

Anavex Life Sciences Earnings Call Transcript: Q4 2025

Nov 25, 2025, 8:30 AM EST - 7 months ago

Anavex Life Sciences Annual report: Q4 2025

Nov 25, 2025, 8:30 AM EST - 7 months ago

Anavex Life Sciences Earnings release: Q4 2025

Nov 25, 2025, 7:30 AM EST - 7 months ago

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Nov 19, 2025, 7:30 AM EST - 8 months ago

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Nov 18, 2025, 7:30 AM EST - 8 months ago

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Nov 14, 2025, 7:30 AM EST - 8 months ago

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Oct 29, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group

Oct 10, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'

Oct 2, 2025, 7:35 AM EDT - 9 months ago

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Oct 2, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 30, 2025, 8:30 AM EDT - 9 months ago

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial

Sep 9, 2025, 1:00 PM EDT - 10 months ago

Anavex Life Sciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:30 AM EDT - 10 months ago

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

Sep 2, 2025, 7:30 AM EDT - 10 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Aug 26, 2025, 7:30 AM EDT - 11 months ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Aug 20, 2025, 7:30 AM EDT - 11 months ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Anavex Life Sciences Earnings Call Transcript: Q3 2025

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Anavex Life Sciences Quarterly report: Q3 2025

Aug 12, 2025, 8:30 AM EDT - 11 months ago

Anavex Life Sciences Earnings release: Q3 2025

Aug 12, 2025, 7:30 AM EDT - 11 months ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Aug 5, 2025, 7:30 AM EDT - 11 months ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Anavex Life Sciences Registration statement: Registration Filing

May 14, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q2 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Quarterly report: Q2 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings release: Q2 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Anavex Life Sciences Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Anavex Life Sciences Proxy statement: Proxy Filing

Apr 23, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 7, 2025, 3:45 PM EDT - 1 year ago

Anavex Life Sciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 5, 2025, 11:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 9:50 AM EST - 1 year ago

Anavex Life Sciences Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 12, 2025, 8:30 AM EST - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q1 2025

Feb 12, 2025, 8:30 AM EST - 1 year ago

Anavex Life Sciences Quarterly report: Q1 2025

Feb 12, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

pipilongstocking Jul. 4 at 8:11 PM

$AVXL https://youtu.be/p31snYad0r4?is=-A0ojCFRf_PsxPgR

0 · Reply

MoneyHungry101 Jul. 4 at 1:01 AM

$AVXL @MayoMobile what is your personal opinion after going through the full report? Are you still holding same position or made any changes? If you like to share? TIA

3 · Reply

pipilongstocking Jul. 3 at 9:48 PM

$AVXL https://x.com/tuckercarlson/status/2073089491896791320?s=46

4 · Reply

Sand_Pebble Jul. 3 at 4:52 PM

0 · Reply

old_salt Jul. 3 at 2:09 PM

$AVXL 💪

0 · Reply

Goodhealth Jul. 3 at 11:03 AM

$AVXL https://www.nature.com/articles/s41556-026-02009-4

0 · Reply

Littlewolf71 Jul. 2 at 11:31 PM

$AVXL

0 · Reply

AntonioChigurh Jul. 2 at 11:29 PM

$AVXL from $31.50 to $2.73 Great Ride!!

0 · Reply

Series4Guy Jul. 2 at 9:24 PM

$AVXL no news today is good news

1 · Reply

Public_Accountant1 Jul. 2 at 7:53 PM

2 · Reply

Hosai Jul. 2 at 6:42 PM

$AVXL Another interesting paper on COL24A1 here from a Nature paper that came out a few days ago. See Chat gpt summary in this post - https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177755293 https://www.nature.com/articles/s41556-026-02009-4

2 · Reply

DollarRollers Jul. 2 at 5:49 PM

Looks like everyone is moving to ticker BMGL now! BMGL is HALTED UP NOW ! China mafia sending it 500%!! $AVXL $SHOP $RIVN $TNXP REOI

1 · Reply

Georgejj Jul. 2 at 4:02 PM

$AVXL Expect that well over 1 million shares of AVXL stock will be bought today!!! Good luck and GOD bless,

1 · Reply

Rudedog_1963 Jul. 2 at 3:34 PM

$AVXL $ANAVEX$

0 · Reply

jcolespartan Jul. 2 at 3:26 PM

$AVXL Actually we need compliance announcement filing within the two weeks. I believe July 21st is the deadline.

1 · Reply

TwistedNipple Jul. 2 at 2:47 PM

$AVXL its a simple announcement. Planned phase 3 with partner. Instant boom....no?

1 · Reply

Sand_Pebble Jul. 2 at 2:44 PM

$AVXL still holding just under 31k shares. I don't know if it's patience, stubbornness or insanity. But I ain't selling at these prices regardless.

5 · Reply

Filldagap Jul. 2 at 2:19 PM

$AVXL Still holding about 130k shares and being patient.

2 · Reply

redbugs Jul. 2 at 1:47 PM

$AVXL series...so where are we? Dead silence from the company. Still holding. I have not sold although i take incoming from my family about avxl circumstance. I have hope but not much. Do not want a low ball buyout. Desire a partner to play this out.

2 · Reply

Sand_Pebble Jul. 2 at 12:19 PM

$AVXL good thing I showed some restraint by not making a snide comment on that opening single share, up 3% to 2.65 in pre. That following 10k block afterwards was more reassuring & a solid trade.

1 · Reply

hbkstockislife Jul. 2 at 4:00 AM

$AVXL is missing still Here ..This used to be printing machine Company back in the days

0 · Reply

Georgejj Jul. 2 at 1:44 AM

$AVXL Sigma-1 receptor agonist SA4503 improves cerebral protective effects in an extracorporeal cardiopulmonary resuscitation rat model https://pmc.ncbi.nlm.nih.gov/articles/PMC13316324/ Good luck and GOD bless,

1 · Reply

Market Cap	255.78M
Revenue (ttm)	0.00
Net Income (ttm)	-46.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,175,000
Avg Vol	1,241,148
Day's Range	N/A - N/A
Shares Out	92.67M
Stochastic %K	88%
Beta	1.14
Analysts	Sell
Price Target	$20.00